[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627160":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":27,"responsibleParty":41,"collaborators":11,"id":44,"slug":11,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tunlametinib","EXPERIMENTAL",null,[13],"Drug: tunlametinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","tunlametinib","Tunlametinib will be administered at a dose of 12 mg orally, twice daily, continuously, in 4-week treatment cycles. Study treatment will continue until the occurrence of intolerable toxicity, PD, withdrawal of consent, initiation of new anti-tumor therapy, death, or when the investigator judges the risk outweighs the benefit, or the study is terminated\u002Fends (whichever occurs first).",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Yu Wang","CONTACT","86-021-64175590","65805","neck130@sina.com",[28],{"facility":29,"status":30,"city":31,"state":11,"zip":11,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","China",{"type":34,"coordinates":35},"Point",[36,37],121.45806,31.22222,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},{"type":42,"investigatorFullName":22,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Chief of Head and Neck Surgery","100627160",false,"NCT07445022","RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma","A Prospective, Open-Label, Multicenter, Real-World Study to Evaluate the Efficacy and Safety of Tunlametinib in Patients With NRAS-Mutant Advanced Melanoma","Inclusion Criteria:\n\n* Aged ≥18 years (inclusive), male or female;\n* Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;\n* Prior genetic testing results showing positive NRAS mutation;\n* Patients who have failed prior anti-PD-1\u002FPD-L1 therapy;\n* Able to take oral medications;\n* Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements.\n\nExclusion Criteria:\n\n* Currently participating in other clinical trials of drugs;\n* Patients who are pregnant or breastfeeding;\n* Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion;\n* Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data.","ALL","18 Years",{"count":53,"type":54},110,"ESTIMATED","INTERVENTIONAL",[57],"PHASE4","This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1\u002FPD-L1 therapy.",[60],"Melanoma Advanced","2026-02-25",{"date":63,"type":64},"2026-03-03","ACTUAL",{"date":66,"type":64},"2026-01-28",{"date":68,"type":54},"2029-01-31",{"name":5,"class":6},1]